325 mg aspirin and plavix

Size: px
Start display at page:

Download "325 mg aspirin and plavix"

Transcription

1 325 mg aspirin and plavix Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin vs. Plavix,. 200 mg, 300 mg, 325 mg, 600 mg month a go and i am still taking aspirin Plavix and rock-club.net Created by Fantom Crestor 10 mg and Concor 5 mg sometime i. Which one is expensive, Aspirin or Plavix? According to drugs.com: The cost for Aspirin tablet 325 mg is around $6.4 for a supply of 20 tablets Plavix (clopidogrel) is a cheap, generically available blood thinner that protects you from clots after you've had a heart attack or surgery. Ecotrin ( aspirin ) can be. I then was put on Aspirin ( 325 mg ), Plavix (75 mg ), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications How long can a person take both Plavix (75 mg ) and aspirin ( 325 mg )? Asked 13 Sep 2010 by ceearruu Active. On Plavix 75mg & Aspirin 325 mg. I have to say, Jim, that a full 325 mg aspirin plus 150 mg of Plavix is a gorilla dose. As a caveat. When taking my 75mg of Plavix and 81mg aspirin 1 1/2 years ago. When do you take your Plavix and Aspirin. After taking Plavix from Oct june 2012 My Cardiologist changed me to Bayer Aspirin 325 mg in place of the Plavix. 1 Answer - Posted in: plavix, aspirin, doctor - Answer: discuss your concerns with the Cardiologist after finding out why your. Aspirin dose 80 mg, 325 mg for heart health,. Plavix is the current standard treatment among so. A baby aspirin is 91 mg while a regular aspirin is 325 mg. Q. I am taking Plavix and Zantac. Is this dangerous too? I had a heart attack and a stent was put in my artery. I then was put on Aspirin (325 mg), Plavix (75 mg), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications. My cardiologist reduced aspirin to 81 mg. I don't. Jan 30, However, the impact of the aspirin dose on the antiplatelet potency of clopidogrel is unclear. We sought to compare the antiplatelet profile of aspirin 81 mg (n = 252 ) versus aspirin 325 mg (n = 459) before and during conventional clopidogrel loading (300 mg), and/or clopidogrel maintenance (75 mg/daily). The recently completed SPS3 trial enrolled subjects with MRI-proven small subcortical ( lacunar ) infarcts within six months of the index event to daily aspirin 325 mg/placebo vs aspirin 325 mg/clopidogrel 75 mg and more aggressive (< 130 mm Hg) vs less aggressive ( mm Hg) systolic blood pressure targets in a. The mechanism of action for aspirin's stroke prevention is the inhibition of prostaglandin synthesis action to prevent the formation of platelet-aggregating substance. The usual dose for this indication in adults is mg/day.. The usual dose is clopidogrel 75mg tablet and an additional aspirin 325mg tablet a day. Aug 30, Methods. We conducted a double-blind, multicenter trial involving 3020 patients with recent symptomatic lacunar infarcts identified by magnetic resonance imaging. Patients were randomly assigned to receive 75 mg of clopidogrel or placebo daily; patients in both groups received 325 mg of aspirin daily. The CAPRIE trial showed that long-term therapy (mean, 1.91 years) with 75 mg per day clopidogrel gave an overall reduction in thrombotic events compared with 325 mg per day aspirin in patients at high risk of vascular occlusion. This

2 was particularly significant in patients with peripheral arterial disease (relative risk. Aug 1, Warfarin and the combination of aspirin and clopidogrel should not be used in the prevention of ischemic stroke. patients with a previous stroke received clopidogrel (75 mg) and aspirin (325 mg) ) or clopidogrel alone for 18 months.25 Combination therapy was not more effective than clopidogrel alone in. 1 Answer - Posted in: plavix, aspirin - Answer: Plavix is licensed to prevent blood clots from forming after having a. Jul 4, The efficacy of clopidogrel (75 mg daily) in preventing recurrent vascular events in patients who suffered a recent MI, stroke or symptomatic established PAD comparing with aspirin (325 mg daily) was approved in CAPRIE (Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events study). CAPRIE was a. Aspirin dose 80 mg, 325 mg for heart health, blood thinning What is the right dose of aspirin for heart attack prevention? Recommendations based on health and medical. In terms of aspirin therapy, a daily baby aspirin may be the best dose. Aspirin is used to treat fever, pain, and inflammation in the body. It also prevents blood clots, stroke, chest pain, and heart attack in certain people. My cardiologists suggested I read about the DAPT trials in regards to Plavix-aspirin aspirin therapy and the length of therapy. I had 2 des, which are first generation, 15. Plavix Dosage and Administration Acute Coronary Syndrome. In patients who need an antiplatelet effect within hours, initiate Plavix with a single 300-mg oral loading. n engl j med 352;3 january 20, 2005 clopidogrel versus aspirin and esomeprazole to prevent ulcer bleeding 239 t is estimated that during the past 75 mg PO daily in combination with aspirin ( mg/day PO), with or without a 300 mg PO loading dose or thrombolytics. Clinical practice guidelines recommend. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. WebMD provides information about common drug or vitamin interactions for Plavix Oral. For self-medication in TEENren 12 years of age, mg every 4 hours (maximum 4 g daily) or 1 g every 6 hours as necessary For self-medication in How long can a person take both Plavix (75 mg ) and aspirin ( 325 mg )? Asked 13 Sep 2010 by ceearruu Active. On Plavix 75mg & Aspirin 325 mg. Aspirin dose 80 mg, 325 mg for heart health,. Plavix is the current standard treatment among so. A baby aspirin is 91 mg while a regular aspirin is 325 mg. Which one is expensive, Aspirin or Plavix? According to drugs.com: The cost for Aspirin tablet 325 mg is around $6.4 for a supply of 20 tablets Compare Aspirin vs. Plavix,. 200 mg, 300 mg, 325 mg, 600 mg month a go and i am still taking aspirin Plavix and Crestor 10 mg and Concor 5 mg sometime i. Plavix (clopidogrel) is a cheap, generically available blood thinner that protects you from clots after you've had a heart attack or surgery. Ecotrin ( aspirin ) can be. I then was put on Aspirin ( 325 mg ), Plavix (75 mg ), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. 1 Answer - Posted in: plavix, aspirin, doctor - Answer: discuss your concerns with the Cardiologist after finding out why your. I have to say, Jim, that a full 325 mg aspirin plus 150 mg of Plavix is a gorilla dose. As a caveat. When taking my 75mg of Plavix and 81mg aspirin 1 1/2 years ago. When do you take your Plavix and Aspirin. After taking Plavix from Oct june 2012 My Cardiologist changed me to Bayer Aspirin 325 mg in place of the Plavix. Jan 30, However, the impact of the aspirin dose on the antiplatelet potency of clopidogrel is unclear. We sought to compare the antiplatelet profile of aspirin 81 mg (n = 252 ) versus aspirin 325 mg (n = 459) before and during conventional clopidogrel loading (300 mg), and/or clopidogrel maintenance (75 mg/daily). The recently completed SPS3 trial enrolled subjects with MRI- proven small subcortical ( lacunar ) infarcts within six months of the index event to daily

3 aspirin 325 mg/placebo vs aspirin 325 mg/clopidogrel 75 mg and more aggressive (< 130 mm Hg) vs less aggressive ( mm Hg) systolic blood pressure targets in a. Q. I am taking Plavix and Zantac. Is this dangerous too? I had a heart attack and a stent was put in my artery. I then was put on Aspirin (325 mg), Plavix (75 mg), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications. My cardiologist reduced aspirin to 81 mg. I don't. The mechanism of action for aspirin's stroke prevention is the inhibition of prostaglandin synthesis action to prevent the formation of platelet-aggregating substance. The usual dose for this indication in adults is mg/day.. The usual dose is clopidogrel 75mg tablet and an additional aspirin 325mg tablet a day. Aug 1, Warfarin and the combination of aspirin and clopidogrel should not be used in the prevention of ischemic stroke. patients with a previous stroke received clopidogrel (75 mg) and aspirin (325 mg) ) or clopidogrel alone for 18 months.25 Combination therapy was not more effective than clopidogrel alone in. Aug 30, Methods. We conducted a double-blind, multicenter trial involving 3020 patients with recent symptomatic lacunar infarcts identified by magnetic resonance imaging. Patients were randomly assigned to receive 75 mg of clopidogrel or placebo daily; patients in both groups received 325 mg of aspirin daily. Jul 4, The efficacy of clopidogrel (75 mg daily) in preventing recurrent vascular events in patients who suffered a recent MI, stroke or symptomatic established PAD comparing with aspirin (325 mg daily) was approved in CAPRIE (Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events study). CAPRIE was a. The CAPRIE trial showed that long-term therapy (mean, 1.91 years) with 75 mg per day clopidogrel gave an overall reduction in thrombotic events compared with 325 mg per day aspirin in patients at high risk of vascular occlusion. This was particularly significant in patients with peripheral arterial disease (relative risk. 1 Answer - Posted in: plavix, aspirin - Answer: Plavix is licensed to prevent blood clots from forming after having a. My cardiologists suggested I read about the DAPT trials in regards to Plavix-aspirin aspirin therapy and the length of therapy. I had 2 des, which are first generation, 15. For self-medication in TEENren 12 years of age, mg every 4 hours (maximum 4 g daily) or 1 g every 6 hours as necessary For self-medication in. Aspirin is used to treat fever, pain, and inflammation in the body. It also prevents blood clots, stroke, chest pain, and heart attack in certain people. WebMD provides information about common drug or vitamin interactions for Plavix Oral. Aspirin dose 80 mg, 325 mg for heart health, blood thinning What is the right dose of aspirin for heart attack prevention? Recommendations based on health and medical. In terms of aspirin therapy, a daily baby aspirin may be the best dose. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. n engl j med 352;3 january 20, 2005 clopidogrel versus aspirin and esomeprazole to prevent ulcer bleeding 239 t is estimated that during the past 75 mg PO daily in combination with aspirin ( mg/day PO), with or without a 300 mg PO loading dose or thrombolytics. Clinical practice guidelines recommend. Plavix Dosage and Administration Acute Coronary Syndrome. In patients who need an antiplatelet effect within hours, initiate Plavix with a single 300-mg oral loading. 1 Answer - Posted in: plavix, aspirin, doctor - Answer: discuss your concerns with the Cardiologist after finding out why your. I then was put on Aspirin ( 325 mg ), Plavix (75 mg ), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications. I have to say, Jim, that a full 325 mg aspirin plus 150 mg of Plavix is a gorilla dose. As a caveat. When taking my 75mg of Plavix and 81mg aspirin 1 1/2 years ago How long can a person take both Plavix (75 mg ) and aspirin ( 325 mg )? Asked 13 Sep 2010 by ceearruu Active. On Plavix 75mg & Aspirin 325

4 mg. Which one is expensive, Aspirin or Plavix? According to drugs.com: The cost for Aspirin tablet 325 mg is around $6.4 for a supply of 20 tablets Aspirin dose 80 mg, 325 mg for heart health,. Plavix is the current standard treatment among so. A baby aspirin is 91 mg while a regular aspirin is 325 mg. When do you take your Plavix and Aspirin. After taking Plavix from Oct june 2012 My Cardiologist changed me to Bayer Aspirin 325 mg in place of the Plavix Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin vs. Plavix,. 200 mg, 300 mg, 325 mg, 600 mg month a go and i am still taking aspirin Plavix and Crestor 10 mg and Concor 5 mg sometime i. Plavix (clopidogrel) is a cheap, generically available blood thinner that protects you from clots after you've had a heart attack or surgery. Ecotrin ( aspirin ) can be. The CAPRIE trial showed that long-term therapy (mean, 1.91 years) with 75 mg per day clopidogrel gave an overall reduction in thrombotic events compared with 325 mg per day aspirin in patients at high risk of vascular occlusion. This was particularly significant in patients with peripheral arterial disease (relative risk. 1 Answer - Posted in: plavix, aspirin - Answer: Plavix is licensed to prevent blood clots from forming after having a. The recently completed SPS3 trial enrolled subjects with MRI-proven small subcortical ( lacunar ) infarcts within six months of the index event to daily aspirin 325 mg/placebo vs aspirin 325 mg/clopidogrel 75 mg and more aggressive (< 130 mm Hg) vs less aggressive ( mm Hg) systolic blood pressure targets in a. Jul 4, The efficacy of clopidogrel (75 mg daily) in preventing recurrent vascular events in patients who suffered a recent MI, stroke or symptomatic established PAD comparing with aspirin (325 mg daily) was approved in CAPRIE (Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events study). CAPRIE was a. Q. I am taking Plavix and Zantac. Is this dangerous too? I had a heart attack and a stent was put in my artery. I then was put on Aspirin (325 mg), Plavix (75 mg), and Zantac because I have stomach ulcer. I had sever nose bleeding after 2 weeks taking the above medications. My cardiologist reduced aspirin to 81 mg. I don't. Aug 1, Warfarin and the combination of aspirin and clopidogrel should not be used in the prevention of ischemic stroke. patients with a previous stroke received clopidogrel (75 mg) and aspirin (325 mg) ) or clopidogrel alone for 18 months.25 Combination therapy was not more effective than clopidogrel alone in. The mechanism of action for aspirin's stroke prevention is the inhibition of prostaglandin synthesis action to prevent the formation of platelet-aggregating substance. The usual dose for this indication in adults is mg/day.. The usual dose is clopidogrel 75mg tablet and an additional aspirin 325mg tablet a day. Aug 30, Methods. We conducted a double-blind, multicenter trial involving 3020 patients with recent symptomatic lacunar infarcts identified by magnetic resonance imaging. Patients were randomly assigned to receive 75 mg of clopidogrel or placebo daily; patients in both groups received 325 mg of aspirin daily. Jan 30, However, the impact of the aspirin dose on the antiplatelet potency of clopidogrel is unclear. We sought to compare the antiplatelet profile of aspirin 81 mg (n = 252 ) versus aspirin 325 mg (n = 459) before and during conventional clopidogrel loading (300 mg), and/or clopidogrel maintenance (75 mg/daily). Aspirin dose 80 mg, 325 mg for heart health, blood thinning What is the right dose of aspirin for heart attack prevention? Recommendations based on health and medical. n engl j med 352;3 january 20, 2005 clopidogrel versus aspirin and esomeprazole to prevent ulcer bleeding 239 t is estimated that during the past WebMD provides information about common drug or vitamin interactions for Plavix Oral. Aspirin is used to treat fever, pain, and inflammation in the body. It also prevents blood clots, stroke, chest pain, and heart attack in certain people. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions,

5 warnings, patient labeling, reviews, and related medications. For self-medication in TEENren 12 years of age, mg every 4 hours (maximum 4 g daily) or 1 g every 6 hours as necessary For self-medication in. Plavix Dosage and Administration Acute Coronary Syndrome. In patients who need an antiplatelet effect within hours, initiate Plavix with a single 300-mg oral loading. In terms of aspirin therapy, a daily baby aspirin may be the best dose. My cardiologists suggested I read about the DAPT trials in regards to Plavix-aspirin aspirin therapy and the length of therapy. I had 2 des, which are first generation, mg PO daily in combination with aspirin ( mg/day PO), with or without a 300 mg PO loading dose or thrombolytics. Clinical practice guidelines recommend.

Plavix duration of effect

Plavix duration of effect Plavix duration of effect The Borg System is 100 % Plavix duration of effect Jan 20, 2015. If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications

More information

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients - MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis

More information

Eliquis and plavix combination therapy

Eliquis and plavix combination therapy Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e

- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e -1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery

More information

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals. OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic

More information

Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets

Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets Read this Medication Guide before you start taking Plavix and each time you get a refill. There may be new information. This Medication

More information

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish

More information

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016 Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss

More information

Discussion guide. Questions to bring to your next doctor s appointment. Notes

Discussion guide. Questions to bring to your next doctor s appointment. Notes Discussion guide Questions to bring to your next doctor s appointment As someone who has had a heart attack or has peripheral arterial disease (PAD), it s important to lower your chance of having a heart

More information

Antithrombotics 201: Aspirin and USPSTF. Presented by: Craig Williams, PharmD., BCPS., FNLA; November, Conflicts of Interest: None

Antithrombotics 201: Aspirin and USPSTF. Presented by: Craig Williams, PharmD., BCPS., FNLA; November, Conflicts of Interest: None Antithrombotics 201: Aspirin and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; November, 2016 Conflicts of Interest: None 1 What percent of patients who die within 30 days of an MI die before

More information

ASPIRIN AND VASCULAR DISEASE

ASPIRIN AND VASCULAR DISEASE ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Conflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important

Conflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important Aspirin, primary prevention and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; February 2017 Conflicts of Interest: None Primary prevention of ASCVD is important Myocardial Infarction Incidence

More information

Anti-platelet therapies and dual inhibition in practice

Anti-platelet therapies and dual inhibition in practice Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Vorapaxar for the secondary prevention of atherothrombotic events after myocardial infarction Draft scope (pre-referral)

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Thrombosis Research active studies

Thrombosis Research active studies Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility

More information

Plavix eliquis and aspirin

Plavix eliquis and aspirin Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis

More information

How Long Patietns Will Be on Dual Antiplatelet Therapy?

How Long Patietns Will Be on Dual Antiplatelet Therapy? How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center

More information

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for

More information

Normal cholesterol level for men over 50

Normal cholesterol level for men over 50 Normal cholesterol level for men over 50 Understand what your cholesterol levels mean: Total, LDL, for men and 50 mg per dl their respective numbers have to stay over or under a particular level,. 24-4-2017

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Today, these are all common knowledge, especially in this wonderful age of the Internet, where Dr. Google is on-call 24/7.

Today, these are all common knowledge, especially in this wonderful age of the Internet, where Dr. Google is on-call 24/7. MY column on Aspirin, the Wonder Drug came out in 2002 when this common household item was on the spotlight for sometime for its new role in staving off heart attack, medically termed Acute Myocardial

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Dental Management Considerations for Patients on Antithrombotic Therapy

Dental Management Considerations for Patients on Antithrombotic Therapy Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine

More information

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Is there enough evidence for DAPT after endovascular intervention for PAOD? Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill.

MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. There may be new information. This Medication Guide does not

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents

More information

Summary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid)

Summary of the risk management plan (RMP) for Clopidogrel/Acetylsalicylic acid Teva (clopidogrel / acetylsalicylic acid) EMA/411850/2014 London, 28 July 2014 Summary of the risk management plan (RMP) for (clopidogrel / acetylsalicylic acid) This is a summary of the risk management plan (RMP) for, which details the measures

More information

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no

More information

Patient & Family Guide. Aspirin.

Patient & Family Guide. Aspirin. Patient & Family Guide Aspirin 2017 www.nshealth.ca Aspirin Brand name: Bayer Aspirin There are many other brands of this medicine available. My medicine is called: Why do I need this medicine? Aspirin

More information

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events Date: August 21, 2008 Refer to: Carole Copeland (OUS) Eli Lilly and Company 317-277-3661 (office) 317-610-6196 (cell) Tammy Hull (U.S.A.) Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell)

More information

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes

More information

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La

More information

TOP CLINICAL TRIALS of 2018 to Impact Your Practice - ASCEND (& REDUCE IT)

TOP CLINICAL TRIALS of 2018 to Impact Your Practice - ASCEND (& REDUCE IT) TOP CLINICAL TRIALS of 2018 to Impact Your Practice - ASCEND (& REDUCE IT) David de Padua Brasil, MD, MSc, FACC Lavras Federal University/UFLA School of Medicine/Department of Health - Lavras, MG, Brazil

More information

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

CEREBRO VASCULAR ACCIDENTS

CEREBRO VASCULAR ACCIDENTS CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA

More information

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,

More information

Optimal medical therapy in patients with stable CAD

Optimal medical therapy in patients with stable CAD Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic

More information

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation

HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation

More information

7 th Munich Vascular Conference

7 th Munich Vascular Conference 7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.

More information

Subject Expert. Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO

Subject Expert. Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO Stroke 101 Subject Expert Michelle Whaley MSN, CNS, CCNS, ANVP-BC Swedish Medical Center Englewood, CO 2 Objectives Types of strokes Stroke warning signs Stroke risk factors Medical test performed following

More information

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support

More information

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to

More information

Use of Aspirin for primary prevention of cardiovascular disease - USPSTF guideline changes

Use of Aspirin for primary prevention of cardiovascular disease - USPSTF guideline changes Use of Aspirin for primary prevention of cardiovascular disease - USPSTF guideline changes Pawan Hari MD MPH Director cardiac catheterization laboratory Dr. Hari indicated no potential conflict of interest

More information

Author: K. Ketchum Date: July 2015

Author: K. Ketchum Date: July 2015 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine

Acute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute

More information

Arteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante

Arteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital

Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

Should I take aspirin? The risks and benefits. Podcast created by Lia Schmitz, Pharm.D. for Island Drug. March 6, 2013

Should I take aspirin? The risks and benefits. Podcast created by Lia Schmitz, Pharm.D. for Island Drug. March 6, 2013 Should I take aspirin? The risks and benefits Podcast created by Lia Schmitz, Pharm.D. for Island Drug March 6, 2013 Aspirin is one of the oldest medicines, useful as a pain reliever, antiinflammatory,

More information

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet

More information

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017 GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional

More information

SESSION 3 11 AM 12:30 PM

SESSION 3 11 AM 12:30 PM SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related

More information

Prof. Jindřich Špinar, MD

Prof. Jindřich Špinar, MD Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head

More information

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD

Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Vascular Protection: Preventing Thrombotic Complications of VTE and PAD Thursday, October 11, 2018, 2:00pm ET Guest Speakers: Geoff Barnes, MD Scott Damrauer, MD Moderators: Tracy Minichiello, MD; Sara

More information

Figure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE

Figure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should

More information

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy

More information

Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial

Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Is the combination of antithrombotics and lowdose anticoagulants worthwhile in PAD The VOYAGER trial Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical

More information

Asprin Bryce Gates Richard hammond Agustin chavez

Asprin Bryce Gates Richard hammond Agustin chavez Asprin Bryce Gates Richard hammond Agustin chavez Who discovered asprins? The discovery of aspirin is customarily said to have resulted from Felix Hoffmann's rheumatic father encouraging his son to produce

More information

(direct) (609) (mobile)

(direct) (609) (mobile) MEDIA Sanofi-aventis Bristol-Myers Squibb Ingrid Görg-Armbrecht Laura Hortas + 33 153-774-625 (direct) (609) 252-4587 +33 686-056-688 (mobile) laura.hortas@bms.com ingrid.goerg-armbrecht@sanofi-aventis.com

More information

Dual Antiplatelet Therapy Made Practical

Dual Antiplatelet Therapy Made Practical Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

Section Editor Scott E Kasner, MD

Section Editor Scott E Kasner, MD 1 of 6 9/29/2013 6:55 PM Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis,

More information

DISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM

DISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole

More information

OUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R.

OUTCOMES WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLASTY Ashok Kumar Arigonda, K. Nagendra Prasad, O. Hareesh, R. INDIAN JOURNAL OF CARDIOVACULAR DIEAE JOURNAL in women (IJCD) 016 VOL 1 IUE 3 ORIGINAL ARTICLE 1 OUTCOME WITH LONGTERM DUAL ANTIPLATELET THERAPY AFTER CORONARY ANGIOPLATY Ashok Kumar Arigonda, K. Nagendra

More information

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Developed in Collaboration with American College of Emergency Physicians and Society for Cardiovascular Angiography and

More information

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose?

Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson

More information

ISCHEMIC HEART DISEASE

ISCHEMIC HEART DISEASE ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,

More information

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,

More information

Liping Liu Dpet. of Neurology and Stroke Center Beijing Tiantan Hospital Capital Medical University

Liping Liu Dpet. of Neurology and Stroke Center Beijing Tiantan Hospital Capital Medical University Liping Liu Dpet. of Neurology and Stroke Center Beijing Tiantan Hospital Capital Medical University Disclosures Conflict of interest disclosures: No Disclosures Funding The CHANCE trial is funded by the

More information

ASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD

ASA PLAVIX AND PREOPERATIVE OPTIMIZATION. John Hann, MD ASA PLAVIX AND PREOPERATIVE OPTIMIZATION John Hann, MD QUESTIONS: WHICH ANTI-PLATELETS DO YOU STOP AND WHEN? 1. 65 yo M with history of stroke on ASA PreOp eval for cataracts surgery 2. 65 yo M with RCRI

More information

Carlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium

Carlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University

More information

C-Reactive Protein and Your Heart

C-Reactive Protein and Your Heart C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory

More information

Xarelto and plavix taken together.

Xarelto and plavix taken together. Toggle navigation Xarelto and plavix taken together. Integrilin (eptifibatide) helps to prevent platelets in your blood from sticking together and forming a blood clot. An unwanted blood clot can occur

More information

Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?

Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science

More information

Antithrombotic. DAPT or OAC?

Antithrombotic. DAPT or OAC? Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts

More information

Prevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano

Prevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

Antithrombotics in Stroke management

Antithrombotics in Stroke management Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,

More information

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic

More information

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict

More information

Nanik Hatsakorzian Pharm.D/MPH

Nanik Hatsakorzian Pharm.D/MPH Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome

More information

Vimovo (delayed-release enteric-coated naproxen with esomeprazole)

Vimovo (delayed-release enteric-coated naproxen with esomeprazole) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.17.01 Subject: Vimovo Page: 1 of 5 Last Review Date: September 18, 2015 Vimovo Description Vimovo (delayed-release

More information